Advances In The Stem Cell Industry: The Future Impact Of Innovation, And An Evaluation Of The Commercial Landscape-Aarkstore Enterprise
This report takes the implications of IPS cells and other developments into account. Some essential technologies are already in place and stem-cell based therapies have already begun to appear in the marketplace. This has enabled the author to build market estimates based on emerging commercial realities. The stem cell market is already divided into three segments—cell-based treatments, umbilical cord blood banking, and the use of stem cells to evaluate the efficacy and safety of new drugs developed by other methods. Global sales reached $410 million in 2008, and will grow to $2.68 billion by 2012. This growth will reach a projected $5.1 billion in 2014, providing a realistic, and even cautious forecast of the commercial potential these segments.
The report also describes the potential for stem cell science as applied to drug discovery and toxicity testing To give a full industry perspective, the report offers profiles of a large number (approximately 50) of companies operating in this field, including all sizes and types of organisation from small start-ups based on a single technology to large concerns with established product portfolios. This report also describes the background of stem cell science and the current status of knowledge in this sphere. The approach does not shirk essential technical detail but it is written in an easily readable style and the depth of information provided is carefully assessed.
Key features of this report
Provides current status of the stem cell market, essential in a fast-moving field where up-to-date knowledge is paramount.Another key quality for a report such as this is that it should be realistic. Whether one describes the glass as half-full or half-empty matters less than describing it as a half glassful. Market forecasts are refined to indicate the potential offered by this exciting new area of technology without ignoring the practical difficulties.The scope for medical applications of stem cell science is broad and the report attempts to give as full a picture as possible, including applications that are as yet in development as well as those which are more advanced.The report also describes the potential for stem cell science as applied to drug discovery and toxicity testingTo give a full industry perspective, the report offers profiles of a large number (approximately 50) of companies operating in this field, including all sizes and types of organisation from small start-ups based on a single technology to large concerns with established product portfolios.The report describes the background of stem cell science and the current status of knowledge in this sphere. The approach does not shirk essential technical detail but it is written in an easily readable style and the depth of information provided is carefully assessed.
Key findings from this report
The main focus of applied stem cell research has been to explore the possibilities of using SCs in regenerative medicine, to replace normal cells and tissues destroyed by disease or trauma.Primary therapeutic targets are nervous system disorders such as Parkinson’s disease and amyotrophic lateral sclerosis; cardiovascular disease including heart failure, myocardial infarction and severe peripheral arterial disease..Stem cell science also offers the prospect of contributing to new drug discovery, for example by providing in vitro targets that can identify promising new candidates before any in vivo work has been undertaken.Cell-based therapies may be divided into those using autologous cells and those using allogeneic cells. Each market has its own characteristics.The world market for cell-based therapies is now estimated at $600 million, but there is great growth potential, given the high prevalence of eligible patients, once appropriate products reach the marketplace.The US accounts for about 90% of the world market but other national markets will make inroads over the coming years, and grow faster than the US market.Attrition among companies and products in the regenerative medicine market indicate that this is a demanding market environment requiring care in the choice of appropriate marketing model.
Key questions answered by this report
What are the main hitherto untreatable conditions for which stem cell therapy may provide new hope of cure?Are embryo or adult stem cells the best prospect for future commercialization?What is the present size of the global stem cell market, and how is it expected to grow?Which are the leading national markets for stem cell products?What is the nature of the ethical objection to stem cell manipulation?What important factors need to be taken into account when formulating a business plan for stem cell commercialization.Names the leading companies with stem cell products in advanced development.Apart from the treatment of disease, what other roles are envisaged for stem cell products?What are induced pluripotent stem cells, and why are they important?Â
BrainstormGenzymeInternational Stem Cell CorporationMedCellMediStemNuVasiveOpexaOsirisPlureon    Table of Contents : Â
Advances in the Stem Cell IndustryExecutive summary 10Background 10Stem cell research and development: scope and status 10Commercial landscape 11Industry landscape 12Chapter 1 Background 16Summary 16Introduction 17The building blocks of life 17About stem cells 18Potency 20Stem cell division 21Stem cell research 21Human ESCs 23Current status of knowledge 24Embryonic stem cells 24Growth and identification of ESCs 25Stimulating ESCs to differentiate 26Adult stem cells 26Cord blood stem cells 29Induced pluripotent stem cells 30Nuclear reprogramming 31Ethical and regulatory issues 33Situation in the US 33European regulations 34Chapter 2 Stem cell research and development: scope and status 38Summary 38Introduction 39Practical applications of stem cells 39Disease treatment 40Amyotrophic lateral sclerosis 40Parkinson’s disease 43Spinal cord injury 44Alzheimer’s disease 46Cancer 48Heart disease 49Peripheral arterial disease 52Type 1 diabetes 55Liver failure 59Graft-versus-host disease 60Stem cell models: applications in drug discovery 61Screening studies 61Toxicity studies 63Practical benefits 64Some skepticism remains 65Chapter 3 Commercial landscape 68Summary 68Resisting the hyperbole 69Market realities 70Cell-based therapy market 70Autologous SC therapy 71Allogeneic SC therapy 71Cord blood banks 71Market drivers 72Market 73Global market estimates and forecasts 74Global market by use 75Global market by country share 76Embryo vs. adult stem cells 77Investment opportunities 78Choosing a viable business model 79Matching the model to the circumstance 80Autologous therapy models 80Allogeneic therapy models 83Chapter 4 Industry landscape 86Summary 86Introduction 87Company profiles 89Aastrom Biosciences, Inc. 89Overview 89Pipeline 90Advanced Cell Technology, Inc. 90Overview 91Pipeline 91Collaboration 92Aldagen 92Overview 92Pipeline 92Collaboration 93Angioblast Systems, Inc. 93Overview 93Pipeline 94Athersys, Inc. 95Overview 95Pipeline 95Collaboration 96Financials 96Bioheart, Inc. 97Overview 97Pipeline 97Bionet 98Overview 99Collaboration 99Brainstorm Cell Therapeutics 99Overview 100Capricor, Inc. 101Overview 101Pipeline 101Collaboration 102Cardio3 BioSciences SA 102Overview 102Cellcyte Genetics 103Overview 103Pipeline 103Collaboration 104Cellerix SA 104Overview 104Pipeline 105CellGenix Technologie Transfer 105Overview 106Cytori Therapeutics, Inc. 107Overview 107Entest BioMedical, Inc. 107Overview 108ES Cell International 108Overview 109EvoStem Finland Oy 109Overview 110Fate Therapeutics, Inc. 110Overview 110Genzyme 112Collaboration 113Financials 113Geron 113Overview 113Pipeline 114Healtheuniverse, Inc. 114Overview 115Innovacell Biotechnologie AG 115Overview 116International Stem Cell Corporation (ISCO) 116Overview 116Financing 118iPierian, Inc. 118Overview 118Ixion Biotechnology, Inc. 119Overview 119Karocell Tissue Engineering AB 120Overview 120MedCell Bioscience Ltd 121Overview 121MediStem, Inc. 122Overview 122Pipeline 123Mesoblast Limit
ed 124Overview 125Nephrogenix 126Overview 126Neuralstem, Inc. 127Overview 127Pipeline 128Collaboration 128OncoStem Pharma 128Overview 128Novocell, Inc. 129Overview 129NuVasive, Inc. 130Overview 130Osiris Therapeutics, Inc. 131Overview 131Pipeline 131Collaboration 132Financials 133Pharmicell Europe GmbH 133Overview 133PrimeGen Biotech 134Overview 135Opexa Therapeutics 136Overview 136Financing 136Financials 137Plureon 137Overview 137Pipeline 138Collaboration 138Proteonomix, Inc. 139Overview 139Regenerative Sciences, Inc. 140Overview 140ReNeuron 140Overview 141Pipeline 141Shenzhen Beike 143Overview 143Stematix, Inc. 143Overview 144StemCells, Inc. 145Overview 145Stem Cell Therapeutics 146Overview 147Stem Cell Therapy International 147Overview 147Stemedica Cell Technologies, Inc. 148Overview 148Stempeutics Research Pvt. Ltd. 149Overview 150t2cure GmbH 150Overview 151TICEBA GmbH 152Overview 152Tristem 153Overview 153Chapter 5 Appendix 154Methodology 154Glossary 155Index 162List of FiguresFigure 1.1: Early embryonic development and later differentiation 19Figure 1.2: Stem cell division 21Figure 1.3: Induced pluripotent stem cells 31Figure 2.4: Stem cell opportunities in disease treatment and R&D 40Figure 3.5: Forces affecting the stem cell market 73Figure 3.6: Key challenges faced when developing autologous therapy 83Figure 4.7: Type and number of regenerative medicine organizations 87List of TablesTable 3.1: Global stem cell market ($m), 2008-14 74Table 3.2: Potential US patient populations for cell-based therapies 75Table 3.3: Stem cell market by main uses ($m), 2008-14 76Table 3.4: Country breakdown of stem cell market ($m), 2008-14 77Table 3.5: Leading cell-based regenerative medicine products 79
  For More information please contact :
http://www.aarkstore.com/reports/Advances-in-the-Stem-Cell-Industry-The-future-impact-of-innovation-and-an-evaluation-of-the-commercial-landscape-34064.html
Other articles you might like;
- Social Apps Gaining Popularity, Mobile Games Reaching Saturation
- Wozniak on Windows Phone: Microsoft Reincarnated Steve Jobs
- Google Drive’s Six Substantial Slip-ups
- Is HTC’s StereoClip The Future of Bluetooth Audio?
- Will Your Next Smartphone Have Super-Science Wonder Glass?
